Dec. 23, 2022— The examples of worsened health outcomes for patients from drug company restrictions on 340B pricing to safety-net hospitals continue to mount. At Riverside Regional Medical Center in Virginia, one discharged patient with diabetes was readmitted to the hospital within days due to delayed access to an insulin medication for which drug companies had restricted … [Read more...]
GlaxoSmithKline Policy Threatens Asthma Care
Feb. 16, 2022– Just days after President Biden spoke out in support of the 340B drug pricing program, drug giant GlaxoSmithKline (GSK) announced it will begin withholding 340B discounts starting in April for most safety-net hospitals. That action will bring the number of drug companies violating the 340B law to 14. In 2021, GSK reported more than $45 billion in global sales, … [Read more...]
Boehringer Ingelheim Joins in the Attacks on 340B
July 12, 2021– The pharmaceutical giant Boehringer Ingelheim (BI), a manufacturer headquartered in Germany, is the latest company to announce it is cutting off discounts to safety-net hospitals participating in the 340B drug pricing program. If BI goes through with its threat on Aug. 1, it will become the seventh drug company to limit 340B discounts despite strong warnings by … [Read more...]
Faces of 340B: Meeting the Mission of a Healthier Community
April 29, 2021 – At MetroHealth in Cleveland, the health providers and the staff who support them work as one to meet the health system’s mission of “leading the way to a healthier you and a healthier community.” One of the key elements that helps turn these words into action is the 340B drug pricing program. MetroHealth is a system with four hospitals, more than 20 health … [Read more...]
Faces of 340B: Breathing Easier
October 16, 2020 – Dan Hargrave was struggling to breathe, and he and his physicians initially were not sure why. He had asthma as a child, but his doctors were not confident this was the cause. Eventually, Dan was diagnosed with chronic obstructive pulmonary disease (COPD). He did not know it at the time, but the 340B drug pricing program would be a key element of how he would … [Read more...]